Thanks Joe -- for pointing out the importance of evaluating sources of information. For those interested, this is from a guide for evaluating Medline (PubMed, GratefulMed) abstracts from the National Library of Medicine (I substituted examples of abstracts on PD): Guide to Medline Abstracts :Three Clues to look for: I. Author's affiliation [AD] - Institutional affiliation and address of the first author, such as a medical school, university, research institute, or pharmaceutical company. Usually listed after the Authors' names. For example: TITLE: Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD. AUTHORS: Nutt JG; Carter JH AUTHOR AFFILIATION: Department of Neurology, School of Medicine, Oregon Health Sciences University, Portland 97201-3098, USA. [log in to unmask] SOURCE: Neurology 2000 Jan 11;54(1):247-50 or TITLE :Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease. AUTHORS:Taylor AC, Beerahee A, Citerone DR, Cyronak MJ, Leigh TJ, Fitzpatrick KL, Lopez-Gil A, Vakil SD, Burns E, Lennox G AUTHOR AFFILIATION: Division of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, Welwyn, Herts, UK. SOURCE : : Pharmacotherapy 1999 Feb;19(2):150-6. II. MESH Headings (Medical Subject Headings) and TYPE OF SUPPORT: If you look at a Full Medline record, it usually includes two lists of MESH Headings MAIN MESH HEADINGS: Describe the major subjects of the article. For example: Antiparkinson Agents Dopamine Agents/*administration & dosage Parkinson Disease/*drug therapy ADDITIONAL MESH HEADINGS: Give more details such as information about the type of study, characteristics of the subjects, *where the funding came from. For example: ADDITIONAL MESH HEADINGS: Female Human Levodopa/administration & dosage Middle Age * Support, Non-U.S. Gov't * Support, U.S. Gov't, P.H.S. Treatment Outcome * There are 3 types of support that can be noted, and a combination of 2 or 3 can be listed for the same study: 1.Support, U.S. Govt, P.H.S. or United States Gov't Supported , N.I.H. (or variations) - research was supported by Public Health Service or NIH 2. Support, U.S. Gov't, Non-P.H.S (Or variations) -research supported by other US Govt agencies 3. Support, Non-U.S. Gov't - supported by American societies, institutes, state govts, universities, private organizations (such as drug companies) or by foreign sources. III. PUBLICATION TYPES : Tells about the type of article, who it was written for, if it is reporting on a single study or clinical trial, or summarizing a number of studies, whether it is an opinion piece (editorial), etc. Some Publication Types are: Clinical Trial [includes all types and phases of clinical trials] - reports results of a single study. Editorial Letter [includes letters to editor] Meta-Analysis - summary combining results a number of studies Multicenter Study News [medical or scientific news] Practice Guideline - specific health care guidelines for practitioners Review Literature [general review article] - gives summary of previously published research articles on a given subject Review, Tutorial - broad review for non-specialist or student Here are some examples: REVIEW TUTORIAL: TITLE: New drugs for the treatment of Parkinson's disease. AUTHORS: LeWitt PA AUTHOR AFFILIATION: Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA. SOURCE: Pharmacotherapy 2000 Jan;20(1 Pt 2):26S-32S CITATION IDS:PMID: 10641989 UI: 20104975 ABSTRACT: Since the introduction of levodopa to treat Parkinson's disease (PD), several new therapies have been directed at improving symptom control, which can decline after a few years of levodopa therapy. Dopaminergic agents can serve as adjuncts or as alternatives to levodopa. In addition, a new class of drugs, catechol-O-methyltransferase inhibitors, can extend the duration of levodopa action. Although surgical options such as pallidotomy offer improvement of parkinsonism beyond the realm of pharmacologic treatment, judicious administration of drugs in combination can generally solve most problems of PD. PUBLICATION TYPES: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL PT : CLINICAL TRIALS example: TITLE : Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease. AUTHOR : Taylor AC, Beerahee A, Citerone DR, Cyronak MJ, Leigh TJ, Fitzpatrick KL, Lopez-Gil A, Vakil SD, Burns E, Lennox G AUTHOR AFFILIATION; Division of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, Welwyn, Herts, UK. ABSTRACT: STUDY OBJECTIVE: To assess the interaction between therapeutic dosages of ropinirole and L-dopa plus a decarboxylase inhibitor administered at steady state in patients with Parkinson's disease. DESIGN. Open, 6-week, overlap trial with random allocation. PATIENTS: Thirty patients with Parkinson's disease not previously treated with dopamine agonists, of whom 28 produced evaluable pharmacokinetic data for ropinirole and 23 for L-dopa. INTERVENTION: Group A (14 patients) received L-dopa for weeks 1-5 and ropinirole in increasing increments for weeks 2-6; group B (16) received ropinirole for weeks 1-5 and L-dopa for weeks 5 and 6. MEASUREMENTS AND MAIN RESULTS: Primary end points were AUC0-8 and Cmax for ropinirole, and AUC0-8, AUC0-infinity and Cmax for L-dopa. Secondary end points were Tmax for ropinirole, and Tmax and half-life for L-dopa. Coadministration with L-dopa at steady state did not affect rate or extent of availability of ropinirole: point estimates of the geometric mean ratio for ropinirole plus L-dopa compared with ropinirole alone for both Cmax and AUC0-8 approximated to unity. The small (16%) increase in peak concentrations of L-dopa on administration with ropinirole is unlikely to be of clinical consequence, as peak concentrations of L-dopa are typically highly variable. CONCLUSION: There are no pharmacokinetic grounds for adjusting dosages of either ropinirole or L-dopa when given in combination. Publication Types: Clinical trial Multicenter study Randomized controlled trial PT : PRACTICE GUIDELINES: example TITLE: Clinical investigation of medicinal products in the treatment of Parkinson's disease (CPMP note for guidance). SOURCE: Eur Neuropsychopharmacol 1999 Sep;9(5):443-9 CITATION IDS: PMID: 10523052 UI: 99450887 ABSTRACT:These notes are intended to provide guidance for the evaluation of drugs in the treatment of Parkinson's disease. They should be read in conjunction with the Directive 75/318/EEC and 83-570/EEC and current and future EC and ICH guidelines, especially those on: Studies in support of special populations: geriatrics (ICH E7). The extent of population exposure to assess clinical safety for drugs intended for long-term treatment in non life threatening conditions . . . . PUBLICATION TYPES: GUIDELINE JOURNAL ARTICLE PRACTICE GUIDELINE TO search Medline go to : Internet Grateful Med - designed for general public use; very user friendly. http:// http://igm.nlm.nih.gov/ or PubMed http://www.ncbi.nlm.nih.gov/PubMed Both are free to search, and provide abstracts, and there are now links to some full-text articles that are available online (not too many yet, but growing). You can also order articles from the National Library of Medicine ( thru Lonesome Doc) but there are charges for these copies. Or you can also request articles through your local public library -- most offer Inter-library loan services, at no charge. Linda Herman